Figure 7.

First‐line management of HIV–PCNSL. Purple: algorithm title; turquoise: non‐systemic anticancer therapies or combination of treatment modalities; white: other aspects of management and non‐treatment aspects. ART, combination antiretroviral therapy; ASCT, autologous stem‐cell transplantation; EMA, European Medicines Agency; FDA, Food and Drug Administration; HD‐MTX, high‐dose methotrexate; HIV, human immunodeficiency virus; HIV–PCNSL, human immunodeficiency virus‐associated primary central nervous system lymphoma; MATRix, rituximab–methotrexate–cytarabine–thiotepa; PCNSL, primary central nervous system lymphoma. ^aRituximab is not EMA or FDA approved for the treatment of PCNSL. ^bWhen the lymphoma resembles that of the immunocompetent host.